Cabaletta Bio (CABA) Return on Capital Employed (2019 - 2025)
Cabaletta Bio's (CABA) quarterly Return on Capital Employed came in at 135.34% in Q4 2025, down 6069.0% year-on-year from 2.27% in Q4 2024, and down 33.66% quarter-over-quarter from 101.25% in Q3 2025.
Cabaletta Bio (CABA) Return on Capital Employed (2019 - 2025) Analysis & Trends
Cabaletta Bio's Return on Capital Employed history runs 7 years deep, the most recent figure standing at 135.34% for Q4 2025.
- On a quarterly basis, Return on Capital Employed fell 6069.0% year-over-year to 135.34% in Q4 2025; TTM through Dec 2025 was 135.34%, a 6069.0% decrease from a year earlier, with the FY2025 full-year figure at 137.89%, down 7280.0% from the prior year.
- Return on Capital Employed declined to 135.34% in Q4 2025 per CABA's latest filing, from 101.25% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 33.31% in Q1 2021 and bottomed at 135.34% in Q4 2025.
- The 5-year median for Return on Capital Employed is 49.14% (2024), against an average of 59.44%.
- Across the five-year window, Return on Capital Employed soared 2015 bps in 2024 and sank 6069 bps in 2025, its largest moves.
- Year by year, Return on Capital Employed stood at 39.89% in 2021, then plunged by 43 bps to 57.09% in 2022, then surged by 34 bps to 37.81% in 2023, then slumped by 97 bps to 74.65% in 2024, then sank by 81 bps to 135.34% in 2025.
- Per Business Quant, the three latest CABA Return on Capital Employed figures stand at 135.34% (Q4 2025), 101.25% (Q3 2025), and 97.78% (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Cabaletta Bio | 182.04 Mn | 182.04 Mn | - | -135.34% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -135.34% |
| Sep 30, 2025 | -101.25% |
| Jun 30, 2025 | -97.78% |
| Mar 31, 2025 | -95.14% |
| Dec 31, 2024 | -74.65% |
| Sep 30, 2024 | -60.89% |
| Jun 30, 2024 | -47.44% |
| Mar 31, 2024 | -37.43% |
| Dec 31, 2023 | -37.81% |
| Sep 30, 2023 | -40.28% |
| Jun 30, 2023 | -44.94% |
| Mar 31, 2023 | -57.58% |
| Dec 31, 2022 | -57.09% |
| Sep 30, 2022 | -56.82% |
| Jun 30, 2022 | -50.83% |
| Mar 31, 2022 | -43.87% |
| Dec 31, 2021 | -39.89% |
| Sep 30, 2021 | -38.39% |
| Jun 30, 2021 | -38.03% |
| Mar 31, 2021 | -33.31% |